Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.
Hepatocellular Carcinoma Non-resectable
ORR, The rate of participants that achieve either a complete response (CR) or a partial response (PR)., up to 3 years|PFS, From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years
OS, Overall survival is defined as time from the start of treatment until death due to any reason., up to 3 years|DOR, The time between the first recorded and objective remission to the first onset of disease progression or all-cause death (whichever happens first), up to 3 years|Safety as measured by number and grade of adverse events, Summary adverse events according to NCI-CTCAE 4.03, up to 3 years
For the first line treatment with untreated locally advanced or metastatic hepatocellular carcinoma, sintilimab injection plus endostar might be one of the treatment choices.